Galenica Struggles In Switzerland As Pandemic Paralyzes Sales
Executive Summary
Galenica struggled to keep up with OTC market growth in Switzerland as the COVID-19 outbreak severely hampered its sales in the opening six months of the year.
You may also be interested in...
Galenica Expands Swiss OTC Offering Through Hedoga Acquisition
Galenica has reinforced its position as the leading player in the Swiss OTC market through the acquisition of Hedoga Group,
Angelini Sets Up In Germany As It Unveils ThermaCare Plans
Angelini is looking to take its recently-acquired ThermaCare brand to the next level by establishing a direct base in Germany to market the product and through a new distribution deal with Norway's Navamedic.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.